- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07940907
Digital Antibiotic Stewardship and Training for Wahudumu wa Afya (DAWA) Project (DAWA)
A Cluster-randomized Trial to Assess the Effectiveness of a Digital Clinical Decision Support System, Training and Mentorship to Reduce Inappropriate Antibiotic Prescribing at Primary Healthcare Facilities in Zanzibar, Tanzania.
The goal of this clinical trial is to learn if a digital decision support tool integrated within an electronic medical record system, with or without training and mentorship for health workers, can reduce unnecessary antibiotic prescribing in patients of all ages (children and adults) who visit primary healthcare clinics in Zanzibar, Tanzania with an acute infectious illness. The main question it aims to answer is:
• Does the proportion of patients who are prescribed an antibiotic go down at clinics using these approaches, compared with clinics providing usual care?
Researchers will compare three groups of clinics to see if the approaches lead to fewer antibiotics being prescribed:
- Digital decision support and dashboard: a tool built into the Zanzibar Electronic Medical Record system (ZanEMR) that guides health workers during consultations, together with a dashboard comparing the antibiotic prescription from that clinic to other clinics.
- Digital decision support and dashboard, plus training and mentorship: the same tool, together with "Antibiotic Stewardship Club" meetings that build knowledge, encourage helpful attitudes and allow health workers to learn from one another
- Usual care: clinics continue to work as normal Whole clinics, rather than individual patients, are assigned by chance to one of the three groups. Participating clinics are public dispensaries or health centers that treat sick children and adults and have ZanEMR in their consultation rooms.
Participants will:
- Visit a participating clinic as usual for an acute infectious illness
- Receive care from health workers who are using the digital tool, taking part in the stewardship club meetings, or providing usual care, depending on their clinic's group
- Be called seven days after their visit by the research team, to record their health status
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
BACKGROUND
Antibiotic prescription is inappropriately high in outpatient primary care settings and are projected to increase over the next years (Sulis et al., 2020). Inappropriate antibiotic prescription is one of the biggest contributors to the development of antibiotic resistance at the individual and population level (Holmes et al., 2016). Consequently, bacterial antimicrobial resistance is directly responsible for 1.3 million deaths a year and rising, as much as malaria and HIV combined (Murray et al., 2022). The World Health Organization (WHO) has declared it as 'one of the biggest threats to global health, food security and development today'.
With over 80% of antibiotic prescription occurring at primary care, the need for antibiotic stewardship programs at the community level is especially important (Duffy et al., 2018).
Clinical decision support systems (CDSS) provide clinical guidance at the point of care, ranging from alerts within an electronic medical record (EMR) system, to comprehensive support throughout every step of the consultation process (often described as clinical decision support algorithms (CDSAs)) (Sutton et al., 2020). In some studies, CDSAs have led to a two to four-fold reduction in antibiotic prescription without increase in morbidity/mortality, while others have shown little to no reduction in antibiotic prescription (Ibrahim et al., 2026).
Despite their potential, many CDSAs have important limitations. Most existing tools focus on paediatric populations, many are not integrated within electronic medical record systems, leading to duplicate data entry, inefficient clinical workflows and poor uptake (Ibrahim et al., 2026).
In Zanzibar, the deployment of the national EMR system for primary healthcare facilities, called ZanEMR (Zanzibar Electronic Medical Record System), started in 2025, offers a unique opportunity to provide decision support to primary care clinicians.
While digital tools can support decision-making, sustained behavior change often requires the combination of multiple interventions including training, mentorship, and audit & feedback (Arnold & Straus, 2005; Mostofian et al., 2015).
OBJECTIVES
Primary objective:
To evaluate the effectiveness of two antibiotic stewardship interventions - both incorporating clinical decision support integrated into an electronic medical record system and one with an additional mentorship/training intervention - to reduce antibiotic prescribing for acute infectious illness in patients of all ages, compared to usual care at primary healthcare facilities.
Secondary objectives include:
Harm: To evaluate that there is no more harm to patients managed in intervention health facilities compared to patients in the control health facilities in terms of worse self-reported clinical status, and severe adverse outcome (hospitalization without referral or dead by day 7)
Feasibility and acceptability: The objective is to determine the feasibility and acceptability of the DAWA interventions by primary healthcare workers receiving the intervention and stakeholders involved in delivering the intervention, as well as determinants of rational antibiotic prescribing by primary healthcare workers exposed to the intervention.
Health Economics: The objective is to perform a cost and cost-effectiveness analysis on the impact of the interventions.
Comparative Effectiveness: The objective is to compare the two different interventions (Clinical decision support, 6 mentorship/training sessions with routine mentorship support vs clinical decision support and routine mentorship support) in terms of their impact on antibiotic prescribing and costs.
Other secondary objectives are to compare the intervention arms with control for the secondary outcomes stated outcome section.
STUDY DESIGN
Main study: DAWA I and II Cluster Randomized Controlled Trial
This three-arm, parallel-group, cluster randomized controlled trial (RCT) will evaluate the effectiveness of two intervention packages aimed at reducing antibiotic prescribing in primary care settings (superiority design), as described in the Arms and Intervention section.
During a first phase (DAWA I), interventions will be deployed as follows:
Intervention arm 1:
- ZanEMR-AS with initial group training and supported mentorship visits
- Audit and Feedback Benchmarking Dashboards
- Antibiotic Stewardship Club
Intervention arm 2:
- ZanEMR-AS with initial group training and supported mentorship visits
- Audit and Feedback Benchmarking Dashboards
Control arm (Usual care):
- ZanEMR: Routinely used electronic medical record, as implemented by the MOHZ, without clinical decision support features for antibiotic stewardship
All study arms continue to use and receive:
- Paper and pdf national guidelines including the Zanzibar Standard Treatment Guidelines, international guidelines including IMCI.
- Routine supervision by district health management teams
During the second phase of the study (DAWA II), health care providers in arm 1 will stop attending Antibiotic Stewardship Club meetings, and both arm 1 and 2 will no longer receive visits supported by the study team. However, arm 1 and 2 will continue to access ZanEMR-AS and Audit and Feedback Dashboards. Routinely entered ZanEMR data will be collected to evaluate long term effectiveness of the different intervention packages.
ANCILLARY STUDIES
Feasibility and acceptability of the interventions by healthcare providers and stakeholders from the Ministry of Health: To assess the feasibility and acceptability of the interventions, semi-structured In-depth Interviews (IDIs) will be conducted with stakeholders from the Ministry of Health, and healthcare providers from facilities randomized to the intervention arms. Participants will be asked about their perception of the different intervention components, their utility, and potential challenges. In addition, we will conduct non-participant observations of antibiotic stewardship clubs, by systematically observing and documenting the discussions between healthcare providers during the monthly Antibiotic Stewardship Club meetings without directly engaging with or influencing the participants.
DAWA III - Before-After Analysis: If the DAWA I cluster RCT demonstrates that the antibiotic stewardship features embedded in ZanEMR (ZanEMR-AS) with or without Antibiotic Stewardship Club meetings shows promise in reducing antibiotic prescribing regardless of statistical significance, then ZanEMR-AS will be scaled across all health facilities using ZanEMR that were not already using ZanEMR-AS during the initial trial. A Before-After analysis will be conducted using routine ZanEMR data to assess changes in antibiotic prescribing behavior across the newly exposed facilities.
This analysis will help evaluate the real-world effectiveness of ZanEMR-AS, under conditions of routine clinical practice, and in a more diverse set of health facilities, located both in Unguja and Pemba islands.
Cost and cost-effectiveness study: The costs and cost-effectiveness of the two interventions strategies will be compared to usual care. This component of the study will help inform policy decisions on the scalability and value-for-money of the interventions.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Grace Mhalu, PhD
- Telefonnummer: +255 655 888 891
- E-post: gmhalu@ihi.or.tz
Studieorter
-
-
Zanzibar
-
Chukwani, Zanzibar, Tanzania, 71000
- Chukwani Health Center
-
Kontakt:
- Grace Mahlu, PhD
- Telefonnummer: +255 655 888 891
- E-post: gmhalu@ihi.or.tz
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Eligibility criteria for participants:
Inclusion Criteria:
- Patients of all ages presenting to participating health facilities for a presumed acute infectious illness (presence of any of the following symptoms or signs for less than 2 weeks: fever, cough, runny nose, sore throat, ear pain, ear discharge, pain urinating, genital complaints, diarrhea, vomiting, skin infection [abscess, pustules]) for their initial consultation related to an acute infectious illness.
Exclusion Criteria:
- Patients presenting for any other acute non-infectious illness-related consultation, including follow-up consultation (planned or unplanned), chronic care consultation, vaccination consultation, or well-child visit consultation
- Patient referred from another health facility
- Patient already included in the study for a previous consultation
Eligibility criteria for Health facilities:
Inclusion criteria:
- Government or government designated primary healthcare facilities (dispensaries) open to the general public
- Health facilities with the Zanzibar Electronic Medical Record system (ZanEMR) available in consultation rooms.
Exclusion criteria:
- Health facilities that are planning to be closed for more than 2 weeks during the conduct of the study
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Hälsovårdsforskning
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Arm 1: Multifaceted Antibiotic Stewardship Intervention
Health facilities in this arm will receive the following interventions:
|
ZanEMR-AS is a set of clinical decision support features to encourage antibiotic stewardship (AS), integrated within the Zanzibar Electronic Medical Record (ZanEMR) System developed by the Ministry of Health. At intervention start, a centralized group training will be conducted, to help healthcare workers understand and effectively use the new EMR features. Additionally, 1-2 visits per health facilities will be conducted to provide on-site mentorship. These visits will be conducted together with the respective District Health Management Teams (DHMTs) in Zanzibar, who conduct regular visits to primary health facilities as part of routine supervision. Audit and feedback benchmarking dashboards will compare antibiotic prescription rates among health facilities and healthcare providers. Overall prescription rates, as well as prescription by WHO AWaRe categories, and by clinical syndromes will be presented. Dashboards will be shared with healthcare providers from participating health facilities and relevant public health officials including District Health Management Teams. Antibiotic Stewardship Club meetings are monthly training and mentorship meetings with healthcare providers, conducted over a period of 6 months (6 meetings in total). The content of the meetings will include:
|
|
Experimentell: Arm 2: Digital Clinical Decision Support Alone
Health facilities in this arm will receive the following interventions:
|
ZanEMR-AS is a set of clinical decision support features to encourage antibiotic stewardship (AS), integrated within the Zanzibar Electronic Medical Record (ZanEMR) System developed by the Ministry of Health. At intervention start, a centralized group training will be conducted, to help healthcare workers understand and effectively use the new EMR features. Additionally, 1-2 visits per health facilities will be conducted to provide on-site mentorship. These visits will be conducted together with the respective District Health Management Teams (DHMTs) in Zanzibar, who conduct regular visits to primary health facilities as part of routine supervision. Audit and feedback benchmarking dashboards will compare antibiotic prescription rates among health facilities and healthcare providers. Overall prescription rates, as well as prescription by WHO AWaRe categories, and by clinical syndromes will be presented. Dashboards will be shared with healthcare providers from participating health facilities and relevant public health officials including District Health Management Teams. |
|
Inget ingripande: Arm 3: Usual care
Health facilities in this arm will pursue usual care, which includes:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Systemic antibiotic prescription
Tidsram: At day 0 (day of initial encounter) (during months 3 to 5 after the initiation of the intervention)
|
Proportion of encounters with a systemic antibiotic prescribed at day 0 among patients enrolled in the study with a suspected infectious illness. This outcome is assessed during months 3 to 5 after the initiation of the interventions (Baseline month 0). |
At day 0 (day of initial encounter) (during months 3 to 5 after the initiation of the intervention)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Clinical status worse
Tidsram: At day 7 after enrollment (during months 3 to 5 after the initiation of the intervention)
|
Proportion of patient encounters for which patients report they are worse compared to baseline (day 0) consultation. |
At day 7 after enrollment (during months 3 to 5 after the initiation of the intervention)
|
|
Severe adverse outcome (composite outcome)
Tidsram: By day 7 after enrollment (during months 3 to 5 after the initiation of the intervention)
|
Proportion of patient encounters for which the patient is
|
By day 7 after enrollment (during months 3 to 5 after the initiation of the intervention)
|
|
Unplanned follow-up consultation
Tidsram: By day 7 after enrollment (during months 3 to 5 after the initiation of the intervention)
|
Proportion of patient encounters for which a patient presents to a health facility for an unplanned follow-up consultation. |
By day 7 after enrollment (during months 3 to 5 after the initiation of the intervention)
|
|
Additional medications
Tidsram: By day 7 after enrollment (during months 3 to 5 after the initiation of the intervention)
|
Proportion of patient encounters for which the patient uses additional medications not prescribed by healthcare provider at the initial encounter. |
By day 7 after enrollment (during months 3 to 5 after the initiation of the intervention)
|
|
Diagnostic-concordant antibiotic prescribing
Tidsram: At day 0 (day of initial encounter) (during months 3 to 5 after the initiation of the intervention)
|
Proportion of patient encounters in which a systemic antibiotic was prescribed when clinically indicated based on the diagnosis, or not prescribed when not indicated*(regardless of antibiotic class, dosage or administration route). *Appropriate antibiotic prescription based on pre-specified matching of ICD-10 diagnoses requiring antibiotics based on national guidelines (and international guidelines if not clear in national guidelines) |
At day 0 (day of initial encounter) (during months 3 to 5 after the initiation of the intervention)
|
|
Antibiotics categorized as an "Access" antibiotic according to the WHO AWARE classification
Tidsram: At day 0 (day of initial encounter) (during months 3 to 5 after the initiation of the intervention)
|
Proportion of patient encounters prescribed an "Access" antibiotic according to the WHO AWARE classification (Access, Watch, Reserve, Not recommended) among all encounters prescribed a systemic antibiotic |
At day 0 (day of initial encounter) (during months 3 to 5 after the initiation of the intervention)
|
|
Long term systemic antibiotic prescription
Tidsram: At day 0 - day of initial encounter (during month 6 to 11)
|
Proportion of encounters presenting for an acute illness with a systemic antibiotic prescribed during months 6 to 11 after intervention initiation (after cessation of antibiotic stewardship club meetings and supported mentorship visits) |
At day 0 - day of initial encounter (during month 6 to 11)
|
|
Diagnostic-concordant systemic antibiotic prescribing (long term)
Tidsram: At day 0 - day of initial encounter (during month 6 to 11)
|
Proportion of patient encounters in which an antibiotic was prescribed when clinically indicated based on the diagnosis, or not prescribed when not indicated* (regardless of antibiotic class, dosage or administration route). Assessed during months 6 to 11 after intervention initiation (after cessation of antibiotic stewardship club meetings and supported mentorship visits). *Appropriate antibiotic prescription based on pre-specified matching of ICD-10 diagnoses requiring antibiotics based on national guidelines (and international guidelines if not clear in national guidelines) |
At day 0 - day of initial encounter (during month 6 to 11)
|
|
Antibiotics categorized as an "Access" antibiotic according to the WHO AWARE classification (long term)
Tidsram: At day 0 - day of initial encounter (during month 6 to 11)
|
Proportion of patient encounters prescribed an "Access" antibiotic according to the WHO AWARE classification (Access, Watch, Reserve, Not recommended) among all encounters prescribed a systemic antibiotic. Assessed during months 6 to 11 after intervention initiation (after cessation of antibiotic stewardship club meetings and supported mentorship visits). |
At day 0 - day of initial encounter (during month 6 to 11)
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Trend in systemic antibiotic prescription over whole study period (exploratory)
Tidsram: At day 0 - initial encounter (during month 0 to 11)
|
Evolution over time of the proportion of encounters presenting for an acute illness with a systemic antibiotic prescribed. Assessed from month 0 to month 11. |
At day 0 - initial encounter (during month 0 to 11)
|
|
Systemic antibiotic prescription in all patients
Tidsram: At day 0 - initial encounter (during month 0-5)
|
Proportion of patient encounters prescribed a systemic antibiotic in all patients (not limited to those with a presumed infectious illness) |
At day 0 - initial encounter (during month 0-5)
|
|
Systemic antibiotic prescription in patients over the whole implementation period
Tidsram: At day 0 - initial encounter (during month 0-5)
|
Proportion of encounters prescribed a systemic antibiotic in patients with a presumed infectious illness, and during the whole implementation period (month 0-5) |
At day 0 - initial encounter (during month 0-5)
|
|
Know-do gap in terms of appropriate systemic antibiotic prescription in all patients in months 3-6
Tidsram: At day 0 - initial encounter (during months 3 to 5 after the initiation of the intervention)
|
Proportion of encounters with or without appropriate systemic antibiotic prescription in comparison to knowledge on what is considered appropriate according to diagnosis*. *Appropriate antibiotic prescription based on pre-specified matching of ICD-10 diagnoses requiring antibiotics based on national guidelines (and international guidelines if not clear in national guidelines) |
At day 0 - initial encounter (during months 3 to 5 after the initiation of the intervention)
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Rainer Tan, PhD, Center for Primary Care and Public Health (Unisanté), University of Lausanne
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- ZAHREC/01/PR/APR/2026/13
- PZ00P3_216330 (Annat bidrag/finansieringsnummer: Swiss National Science Foundation)
- AO_2026-00049 (Annan identifierare: Vaud Cantonal Research Ethics Committee (CER-VD))
- IHI/IRB/No: 19-2026 (Annan identifierare: Ifakara Health Institute Review Board)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
A de-identified version of the data will be made available upon request for research purposes only through a secure data repository.
Because this study uses data from the national EMR, there remains a risk of re-identification, and complete anonymization is not possible. For this reason, the data cannot be made publicly available.
Tidsram för IPD-delning
The IPD and supporting information will be made available at the time of results publiation, with no end date.
Kriterier för IPD Sharing Access
Study protocol is made available publicly via Clinicaltrials.gov SAP will be made available publicly on the study website. IPD will be made available upon request through a secure data repository.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .